S 1317 · 94th Congress · Drugs

A bill to amend the Federal, Food, Drug, and Cosmetic Act, as amended, to require submission of certain additional information by applicants for new drugs; to require the inclusion of certain additional information in drug labeling; and for other purposes.

Introduced 1975-03-24· Sponsored by Sen. Nelson, Gaylord [D-WI]· Senate

Bill Progress

Introduced
2
Committee
3
Senate Vote
4
House
5
Enacted
Latest: Referred to Senate Committee on Labor and Public Welfare.(1975-03-24)

Plain Language Summary

[AI summary unavailable — showing source text] Requires, under the Federal Food, Drug, and Cosemtic Act, applicants for new drugs to submit a statement of biological criteria relating to therapeutic effectiveness and safety which the applicant claims should be specially considered by practitioners who dispense such drug. States that a drug shall be deemed to be mislabeled unless its label contains a statement of biological criteria and performance data.…

Summarized by Claude AI · Non-partisan · For informational purposes only